CoChat

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

England, Bryant, Huang, Tiangui, Karsy, Michael · 2013 · Tumor Biology

The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.

Abstract

Glioblastoma multiforme (GBM) is the most common primary malignancy in the brain and confers a uniformly poor prognosis. Despite decades of research on the topic, limited progress has been made to improve the poor survival associated with this disease. GBM arises de novo (primary GBM) or via dedifferentiation of lower grade glioma (secondary GBM). While distinct mutations are predominant in each subtype, alterations of tumor suppressor p53 are the most common, seen in 25-30 % of primary GBM and 60-70 % of secondary GBM. Various roles of p53 that protect against neoplastic transformation include modulation of cell cycle, DNA repair, apoptosis, senescence, angiogenesis, and metabolism, resulting in an extremely complex signaling network. Mutations of p53 in GBM are most common in the DNA-binding domain, namely within six hotspot mutation sites (codons 175, 245, 248, 249, 273, and 282). These alterations generally result in loss-of-function, gain-of-function, and dominant-negative mutational effects for p53, however, the distinct effect of these mutation types in GBM pathogenesis remain unclear. Signaling alterations downstream from p53 (e.g., MDM2, MDM4, INK4/ARF), p53 isoforms (e.g., p63, p73), and microRNAs (e.g., miR-34) also play critical roles in modulating the p53 pathway. Despite novel mouse models of GBM showing that p53 combined with other mutation generate tumors de novo, the role of p53 as a molecular marker of GBM remains controversial with most studies failing to show an association with prognosis. Regarding treatment in GBM, p53 targeted-gene therapy and vaccinations have reached phase I clinical trials while therapeutic drugs are still in preclinical development. This review aims to discuss the most recent findings regarding the impact of p53 mutations on GBM pathogenesis, prognosis, and treatment.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13277-013-0871-3

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 124 references

Cited by

See all 163

Metadata

Authors
England, B., Huang, T., & Karsy, M.
Affiliations
New York Medical College (US)
Corresponding author
Karsy, Michael
Venue
Tumor Biology
Published
2013-06-05
Volume
34
Issue
4
Pages
2063-2074
ISSN
  • 1010-4283 (ISSN-L)
  • 1423-0380
OpenAlex
W2004432187
Cited by
163
References
125
Citations by year
2026: 4 · 2025: 11 · 2024: 17 · 2023: 9 · 2022: 15 · 2021: 18 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 13 · 2014: 20 · 2013: 1
FWCI
1.76
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Tumor Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
glioblastoma, p53, tumor suppressor, TP53 mutation, mutational hotspots, loss of function, gain-of-function, dominant-negative p53, MDM2, MDM4, p53 isoforms, miR-34, p63, p73, prognosis, cancer vaccination
MeSH terms
Animals, Brain Neoplasms, Glioblastoma, Humans, Prognosis, Signal Transduction, Tumor Suppressor Protein p53, Protein Isoforms, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. https://app.cochat.ai/papers/10.1007/s13277-013-0871-3
The paper
England, B., Huang, T., & Karsy, M. (2013). Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumor Biology. https://doi.org/10.1007/s13277-013-0871-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.